<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04190173</url>
  </required_header>
  <id_info>
    <org_study_id>59-394-14-1</org_study_id>
    <nct_id>NCT04190173</nct_id>
  </id_info>
  <brief_title>Efficacy of PRUcalopride in Critically Ill Patients With Paralytic ILeus</brief_title>
  <acronym>EPRUCIL</acronym>
  <official_title>Efficacy of Prucalopride in Critically Ill Patients With Paralytic Ileus; a Pilot Randomized Double-blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Paralytic ileus is a common intestinal dysfunction in critically ill patients. There are
      still no established the effective medications except correcting the primary causes and
      prokinetics trial which limited in efficacy and potential adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prucalopride, a highly selective 5-HT4 receptor agonist, accelerates gastrointestinal transit
      which may reduce severity of ileus. Furthermore, there is no report of serious cardiac and
      neurological side effects. We aim to evaluate the efficacy of prucalopride as a prokinetic of
      choice on paralytic ileus in critically ill patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">February 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Consecutive enrolment parallel group in intervention group and placebo group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The intervention was blinded to patients, nurse, investigators, and radiologist</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of maximum bowel diameter from baseline at 24 hours</measure>
    <time_frame>after first dose intervention to next 24 hours</time_frame>
    <description>measure on plain abdominal radiography by blinded radiologist</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of maximum bowel diameter from baseline at 48 hours</measure>
    <time_frame>after first dose intervention to next 48 hours</time_frame>
    <description>measure on plain abdominal radiography by blinded radiologist</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of maximum bowel diameter from baseline at 72 hours</measure>
    <time_frame>after first dose intervention to next 72 hours</time_frame>
    <description>measure on plain abdominal radiography by blinded radiologist</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of maximum bowel diameter from baseline at 96 hours</measure>
    <time_frame>after first dose intervention to next 96 hours</time_frame>
    <description>measure on plain abdominal radiography by blinded radiologist</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of maximum bowel diameter from baseline at 120 hours</measure>
    <time_frame>after first dose intervention to next 120 hours</time_frame>
    <description>measure on plain abdominal radiography by blinded radiologist</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of abdominal circumference from baseline at 24 hours</measure>
    <time_frame>after first dose intervention to next 24 hours</time_frame>
    <description>measured at umbilical level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of abdominal circumference from baseline at 48 hours</measure>
    <time_frame>after first dose intervention to next 48 hours</time_frame>
    <description>measured at umbilical level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of abdominal circumference from baseline at 72 hours</measure>
    <time_frame>after first dose intervention to next 72 hours</time_frame>
    <description>measured at umbilical level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of abdominal circumference from baseline at 96 hours</measure>
    <time_frame>after first dose intervention to next 96 hours</time_frame>
    <description>measured at umbilical level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of abdominal circumference from baseline at 120 hours</measure>
    <time_frame>after first dose intervention to next 120 hours</time_frame>
    <description>measured at umbilical level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Paralytic Ileus</condition>
  <condition>Critically Ill</condition>
  <arm_group>
    <arm_group_label>Prucalopride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prucalopride (Trade name: Resolor) 2 mg oral or tube feeding once daily 5 consecutive days Decrease dose to 1 mg once daily in patient with end stage kidney disease or Cirrhosis Child Pugh C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet to mimic Prucalopride made by starch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prucalopride</intervention_name>
    <description>1-2 mg once daily enteral feeding for 5 consecutive days</description>
    <arm_group_label>Prucalopride</arm_group_label>
    <other_name>Resolor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1/2-1 tablet once daily enteral feeding for 5 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Medical patients with APACHE II score &gt;= 15

          -  Paralytic ileus: small bowel diameter &gt;= 4 cm or large bowel diameter &gt;= 6 cm

        Exclusion:

          -  no current prokinetic use

          -  Severe peritonitis or bowel inflammation

          -  ESRD needed hemodialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sawangpong Jandee, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Prince of Songkla University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Panu Wetwittayakhlang, Dr.</last_name>
    <phone>66867725277</phone>
    <email>wet.panu@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine, Prince of Songkla University</name>
      <address>
        <city>Songkhla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Panu Wetwittayakhlang, Dr.</last_name>
      <phone>66867725277</phone>
      <email>wet.panu@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>Panu Wetwittayakhlang</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Prokinetic</keyword>
  <keyword>Prucalopride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ileus</mesh_term>
    <mesh_term>Intestinal Pseudo-Obstruction</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prucalopride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

